Liprolog Mix25

Insulin Lispro, the active ingredient in Liprolog Mix25, is an insulin analog presented as a solution for subcutaneous use. It is used to control blood glucose levels in people with diabetes mellitus, including both type 1 and type 2 disease.

GNH USA supplies Liprolog Mix25 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance.

Insulin Lispro is a rapid‑acting insulin analog used in the management of diabetes mellitus.

- Type 1 diabetes mellitus: provides mealtime glucose control and reduces hyperglycaemic episodes. - Type 2 diabetes mellitus: used as part of intensive insulin regimens to achieve target glycaemic levels.

Insulin Lispro may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypoglycaemia: symptoms of low blood glucose such as sweating, tremor, or confusion. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: increase in body weight associated with improved glycaemic control. - Lipodystrophy: localized changes in subcutaneous fat at injection sites.

Serious or Rare Side Effects: - Severe hypoglycaemia: prolonged or unconscious episodes requiring assistance. - Allergic reactions: urticaria, angioedema, or anaphylaxis. - Lipohypertrophy or lipoatrophy: significant alteration of fat tissue that may affect insulin absorption.

When using Insulin Lispro, several precautions should be observed to ensure safe and effective therapy.

- Dose individualization: adjust the dose based on frequent blood glucose monitoring and clinical response. - Hypoglycaemia risk: educate patients to recognize early signs and have rapid‑acting carbohydrates available. - Renal impairment: use with caution as reduced clearance may increase hypoglycaemia risk. - Pregnancy and lactation: consult a healthcare professional before initiating therapy. - Concomitant medications: review all drugs for potential interactions that may affect glucose control. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin Lispro can interact with other medicines, influencing its glucose‑lowering effect or masking symptoms.

Major Interactions (Avoid): - Beta‑blockers: may blunt the adrenergic warning signs of hypoglycaemia. - Alcohol: can potentiate insulin‑induced hypoglycaemia, especially with missed meals.

Moderate Interactions (Monitor Closely): - Thiazolidinediones: combined use may increase fluid retention and oedema. - ACE inhibitors or ARBs: may enhance insulin sensitivity, requiring dose adjustments. - Loop diuretics: can affect potassium balance, potentially altering insulin action.